ADPT
Adaptive Biotechnologies Corp Health Care Biological Products, (No Diagnostic Substances) Russell 3000
$26.64Close
$4.1BMarket cap
$12.41 – $29.8452-week range
Nov 4, 2026Next report · after the close
Highlights
Strengths
- In a stage-2 uptrend all 8 trend conditions pass
- Leading the market RS 92 · stronger than 92% of stocks over 12 months
Cautions
- Results soon Nov 4, 2026, in 3 days
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
11%
1wk
up 4.4%
price change
1mo
down 7.8%
price change
12-month return
up 58%
market up 11% ·
its own up 48%
F-score
5 / 9
Mixed
Altman Z
5.48
Low risk
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
18.7×
price / book
Earnings yield
down 1.4%
EBIT / enterprise value
Cheaper than
16%
of the market · expensive
Revenue growth
up 55%
year on year
EPS growth
—
latest quarter
Sales growth
up 22%
latest quarter · -14 pts
ROE
down 28%
return on equity
Free cash margin
down 18%
-$48.9M FCF
D/E
0.58
long-term debt / equity
Net debt / EBITDA
—
Interest cover
Lossoperating loss
Piotroski tests
- not yet profitable on its assets
- operating cash flow is negative
- took on more long-term debt
- issued more shares
- profitability improving
- profits backed by cash
- short-term liquidity improved
- gross margin widened
- assets working harder
Repair signals
- Gross margin 59.7% → 74.2%
Trade setup
ATR%
5.6%
$1.48 a day · 2×ATR $23.68
RS
92 / 99
vs the universe
Trend
8 / 8
trend template
Relative volume
2.0×
vs 50-day average
Up/down volume
1.03
50 sessions
Implied move
—
no option chain · report Nov 4, 2026
Trend template · 8 of 8
Screen verdict
Did not qualify for any screen.
Warning signs
- Losing money before interest is even paid The company made an operating loss, so interest is not covered at all - the debt is being serviced from cash reserves, asset sales or new borrowing rather than from the business.
- Shareholders diluted The share count rose 4.1% over the year, from 148m to 154m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
Last reported
Jul 29, 2026
Financials
- Gross 74%
- Net -21%
- Free cash -18%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $98.4M | $154.3M | $185.3M | $170.3M | $179.0M | $277.0M |
| Gross margin | 77% | 68% | 69% | 56% | 60% | 74% |
| Operating income | -$152.8M | -$209.0M | -$200.2M | -$227.0M | -$162.5M | -$57.1M |
| Net income | -$146.2M | -$207.3M | -$200.2M | -$225.2M | -$159.5M | -$59.5M |
| Net margin | -149% | -134% | -108% | -132% | -89% | -21% |
| Earnings per share | -$1.11 | -$1.48 | -$1.40 | -$1.56 | -$1.08 | -$0.39 |
| Free cash flow | -$168.5M | -$254.5M | -$200.3M | -$167.0M | -$98.9M | -$48.9M |
| Free cash margin | -171% | -165% | -108% | -98% | -55% | -18% |
| Cash | $123.4M | $139.1M | $90.0M | $65.1M | $47.9M | $70.5M |
| Long-term debt | — | — | $125.4M | $130.7M | $132.4M | $126.6M |
| Shareholders' equity | $743.3M | $604.0M | $464.2M | $308.4M | $202.7M | $218.8M |
| Shares outstanding | 137.65m | 141.39m | 143.11m | 145.08m | 147.77m | 153.78m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 4, 2026 | Quarterly ↗ | Jun 30, 2026 | 35d |
| May 5, 2026 | Quarterly ↗ | Mar 31, 2026 | 35d |
| Feb 26, 2026 | Annual ↗ | Dec 31, 2025 | 57d |
| Nov 5, 2025 | Quarterly ↗ | Sep 30, 2025 | 36d |
| Aug 5, 2025 | Quarterly ↗ | Jun 30, 2025 | 36d |
| May 1, 2025 | Quarterly ↗ | Mar 31, 2025 | 31d |
| Mar 3, 2025 | Annual ↗ | Dec 31, 2024 | 62d |
| Nov 7, 2024 | Quarterly ↗ | Sep 30, 2024 | 38d |
| Aug 1, 2024 | Quarterly ↗ | Jun 30, 2024 | 32d |
| May 7, 2024 | Quarterly ↗ | Mar 31, 2024 | 37d |
| Feb 29, 2024 | Annual ↗ | Dec 31, 2023 | 60d |
| Nov 9, 2023 | Quarterly ↗ | Sep 30, 2023 | 40d |
Current reports
| Filed | Disclosed |
|---|---|
| Jul 29, 2026 | Results · Director or officer change ↗ |
| Jun 22, 2026 | Material agreement · Agreement ended · New obligation · Unregistered share sale · Other events ↗ |
| Jun 15, 2026 | Other events ↗ |
| Jun 9, 2026 | Shareholder vote ↗ |
| May 5, 2026 | Results ↗ |
| Feb 5, 2026 | Results ↗ |
| Jan 12, 2026 | Results · Regulation FD ↗ |
| Dec 30, 2025 | Other events ↗ |
| Nov 5, 2025 | Results ↗ |
| Aug 18, 2025 | Agreement ended ↗ |
| Aug 5, 2025 | Results ↗ |
| Jun 12, 2025 | Shareholder vote ↗ |